LBA87 Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC)

Journal article

Peer reviewed

T.K. Choueiri, T. Bauer, J.R. Merchan, D.F. McDermott, R. Figlin, E. Arrowsmith, M.D. Michaelson, E. Heath, A.A. D'Souza, S. Zhao, …

Annals of oncology, Vol.34, pp.S1328-S1329

2023-10

Metrics

1 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.147 Prostate Cancer; 1.147.859 Androgen Receptor
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: LBA87 Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC)
Creators: T.K. Choueiri - Dana-Farber Cancer Institute
T. Bauer - Sarah Cannon
J.R. Merchan - University of Miami Health System
D.F. McDermott - Beth Israel Deaconess Medical Center
R. Figlin - Cedars-Sinai Medical Center
E. Arrowsmith - Tennessee Oncology
M.D. Michaelson - Massachusetts General Hospital
E. Heath - The Barbara Ann Karmanos Cancer Institute
A.A. D'Souza - University of Southern California
S. Zhao - Swedish Medical Center
L. Mhamdi - MSD
R. Perini - MSD
D. Vickery - MSD
S. Tykodi - Fred Hutch Cancer Center
Publication Details: Annals of oncology, Vol.34, pp.S1328-S1329
Publisher: Elsevier Ltd
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031945277602976